Suitable for use in pharmacokinetic (PK) assay. Other applications have not been tested but use in such assays should not necessarily be excluded.
This antibody serves as an excellent positive control for Bevacizumab immunogenicity (ADA) assays.
Recommended Working Concentration: 0.05-0.2 μg/ml
Summary
Specifications
Antibody Isotype
IgG
Immunogen
Bevacizumab
Conjugate
Unconjugated
Applications
Application Notes
Suitable for use in pharmacokinetic (PK) assay. Other applications have not been tested but use in such assays should not necessarily be excluded. This antibody serves as an excellent positive control for Bevacizumab immunogenicity (ADA) assays. Recommended Working Concentration: 0.05-0.2 μg/ml
General Notes
Suitable for use in pharmacokinetic (PK) assay. Other applications have not been tested but use in such assays should not necessarily be excluded. This antibody serves as an excellent positive control for Bevacizumab immunogenicity (ADA) assays. Bevacizumab (Avastin) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with colon cancer, lung cancer, glioblastoma, renal-cell carcinoma, and age-related macular degeneration. As angiogenesis inhibitor, Bevacizumab blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).
Target
Alternative Names
Rabbit polyclonal antibody to Avastin; Bevacizumab; Avastin; Anti-V-EGFA antibody
Citations
Publication ()
Have you cited CABT-ZB262 in a publication? Let us know and earn a reward for your research.
My Review for Rabbit Anti-Bevacizumab polyclonal antibody
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
COA
Publication 
Loading ......
